Mersana’s innovative platforms have enabled us to build a pipeline for both Mersana and our collaborators. Our ADCs in preclinical studies and clinical trials are first-in-class molecules that target multiple tumor types with high unmet medical need.
We believe our platforms create an opportunity for ADCs with improved safety and efficacy relative to those developed using first-generation technology.
| Platform | ADC Program | Target | Indication | Preclinical | P1 Dose Escalation | P1 Dose Expansion |
|---|
|
| G1 |
| Dolasynthen |
Emi-Le (XMT-1660) |
B7-H4 |
Multiple Solid Tumors | |
| G2 |
| Immunosynthen |
XMT-2056* |
Novel HER2 Epitope |
Multiple Solid Tumors | |
| Immunosynthen |
XMT-2068 |
Undisclosed |
Undisclosed | |
| Immunosynthen |
XMT-2175 |
Undisclosed |
Undisclosed | |
| Collaborations |
|
| Collaborations: |
Dolasynthen |
|
Undisclosed |
Undisclosed | |
| Immunosynthen |
|
Undisclosed |
Undisclosed | |
| Platform |
ADC Program |
Target |
Indication |
Phase |
| Dolasynthen |
Emi-Le (XMT-1660) |
B7-H4 |
Multiple Solid Tumors |
P1 Dose Expansion |
| Immunosynthen |
XMT-2056* |
Novel HER2 Epitope |
Multiple Solid Tumors |
P1 Dose Escalation |
| XMT-2068 |
Undisclosed |
Undisclosed |
Preclinical |
| XMT-2175 |
Undisclosed |
Undisclosed |
Preclinical |
| Collaborators: |
|
|
|
|
| Dolasynthen |
 |
Undisclosed |
Undisclosed |
Preclinical |
| Immunosynthen |
 |
Undisclosed |
Undisclosed |
Preclinical |
*XMT-2056 is wholly owned by Mersana, with GSK having an exclusive global license option to co-develop and commercialize the candidate.
